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In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, an online 
laboratory surveillance system was established to monitor severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) real-time reverse transcription-PCR (rRT-PCR) testing 
capacities and results. SARS-CoV-2 rRT-PCR testing data were collected from 97 clinical 
laboratories, including 84 medical institutions and 13 independent clinical laboratories in 
Korea. We assessed the testing capacities to utilize SARS-CoV-2 rRT-PCR based on sur-
veillance data obtained from February 7th to June 4th, 2020 and evaluated positive result 
characteristics according to the reagents used and sample types. A total of 1,890,319 
SARS-CoV-2 rRT-PCR testing were performed, 2.3% of which were positive. Strong corre-
lations were observed between the envelope (E) gene and RNA-dependent RNA poly-
merase (RdRp)/nucleocapsid (N) genes threshold cycle (Ct) values for each reagent. No 
statistically significant differences in gene Ct values were observed between the paired up-
per and lower respiratory tract samples, except in the N gene for nasopharyngeal swab 
and sputum samples. Our study showed that clinical laboratories in Korea have rapidly 
expanded their testing capacities in response to the COVID-19 outbreak, with a peak daily 
capacity of 34,193 tests. Rapid expansion in testing capacity is a critical component of the 
national response to the ongoing pandemic.
Key Words: Coronavirus disease 2019, Severe acute respiratory syndrome coronavirus 2, 
Real-time RT-PCR, Laboratory surveillance, Testing capacity, Ct value 
Received: June 27, 2020
Revision received: July 20, 2020
Accepted: September 24, 2020
Corresponding author:  
Hyukmin Lee, M.D.
Department of Laboratory Medicine, Yonsei 
University College of Medicine, 50-1 






Kyoung Ho Roh, M.D.
Department of Laboratory Medicine, 
National Health Insurance Service Ilsan 





* These authors contributed equally to this 
study. 
© Korean Society for Laboratory Medicine
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (https://creativecom-
mons.org/licenses/by-nc/4.0) which permits 
unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the 
original work is properly cited.
The ongoing coronavirus disease 2019 (COVID-19) pandemic 
began in December 2019 in Wuhan, China, with more than 
13,824,739 confirmed cases as of July 18th, 2020 [1]. In Ko-
rea, the first COVID-19 case was confirmed on January 20th, 
2020. Rapid viral transmission during the early phase of CO-
VID-19 has highlighted the importance of laboratory diagnosis 
[2, 3]. Molecular testing is the reference standard for COVID-19 
diagnosis, and real-time reverse transcription-PCR (rRT-PCR) is 
the preferred one [2, 4, 5]. The ability of clinical laboratories to 
perform an appropriate molecular testing for severe acute respi-
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ratory syndrome coronavirus 2 (SARS-CoV-2) detection is criti-
cal for an effective response to the ongoing pandemic. Rapid 
response system, including an emergency use authorization 
(EUA) system for emerging infectious diseases, were estab-
lished by the Korean Centers for Disease Control and Prevention 
(KCDC), Korean Society for Laboratory Medicine (KSLM), and 
the Korean Association of External Quality Assessment Service 
[6, 7]. The first commercial rRT-PCR assay for detecting SARS-
CoV-2 was granted EUA by the Ministry of Food and Drug Safety 
in Korea on February 4th, 2020, and SARS-CoV-2 rRT-PCR 
testing by clinical laboratories began by February 7th, 2020. 
However, as the clinical performance of this assay reagent had 
not been fully evaluated, stringent and continuous quality con-
trol was required [7-9]. Therefore, KSLM COVID-19 Task Force 
established an online laboratory surveillance system to monitor 
SARS-CoV-2 rRT-PCR testing capacities and results. We ana-
lyzed the surveillance data obtained using this system from 
February 7th to June 4th, 2020.
SARS-CoV-2 rRT-PCR data were collected from 97 clinical 
laboratories, including 84 medical institutions and 13 indepen-
dent clinical laboratories; each laboratory submitted the data to 
KSLM daily beginning from February 7th, 2020. Public health 
laboratories, such as the KCDC and local government laborato-
ries, were excluded from this study. Submitted data included: 
(1) the number of tests performed, including the number that 
gave positive, negative, and invalid/indeterminate results for 
SARS-CoV-2, with invalid denoting “failure of both internal con-
trol and target gene amplification” and indeterminate denoting 
that “only some genes were amplified”; (2) detailed information 
on each positive result, including sample type, assay reagent 
and equipment used, and threshold cycle (Ct) values for each 
target gene; and (3) parallel test results to confirm the accept-
ability of new reagent lot. We collected and reviewed the sub-
mitted data once daily and checked errors to ensure data qual-
ity. The Institutional Review Board (IRB) of the National Health 
Insurance Medical Center, Goyang, Korea (IRB No. NHIMC 
2020-04-025) approved the study.
We analyzed Spearman correlation to examine the associa-
tions between the Ct values of genes. We used the Wilcoxon 
signed-rank test to compare the Ct values of paired upper respi-
ratory tract (URT) and lower respiratory tract (LRT) samples with 
Bonferroni correction for multiple comparisons. P <0.05 was 
considered significant. Statistical analyses were performed us-
ing the MedCalc Statistical Software version 19.2.1 (MedCalc 
Software Ltd, Ostend, Belgium).
In total, 1,890,319 SARS-CoV-2 rRT-PCR testing was per-
formed, 2.3% of which were positive (Table 1). The testing 
number and participating laboratories significantly increased by 
the third week of the study period (February 7th to June 4th, 
2020), proportionate to the increase in confirmed cases; with 
over 70,000 testing being performed weekly after the initial two 
weeks, the daily testing capacity (34,193 tests) peaked on May 
29th, 2020 (Fig. 1).
Of the positive results, 13,006 results were initially obtained 
from newly diagnosed COVID-19 patients. Majority of the tests 
were conducted using the PowerChek 2019-nCoV Real-time 
PCR Kit (Kogenebiotech, Seoul, Korea), targeting the envelope 
(E) and RNA-dependent RNA polymerase (RdRp) genes, and 
the Allplex 2019-nCoV Assay (Seegene, Seoul, Korea), targeting 
the E, RdRp, and nucleocapsid (N) genes; these were the first 
and second commercial assays to receive EUA, respectively 
(Supplemental Data Table S1). The parallel test results showed 
low lot‐to‐lot reagent variation (Supplemental Data Table S2). 
Strong correlations were observed between the E and RdRp/N 
Ct values using PowerChek and Allplex (Spearman’s rho > 0.98, 
P <0.001), and lower Ct values were obtained for E than for the 
RdRp or N genes. The median Ct value difference between E 
and RdRp was 0.40 (95% confidence interval [CI], 0.38–0.43) 
for PowerChek. For Allplex, the median Ct value differences be-
tween genes were 1.25 for E and RdRp (95% CI, 1.24–1.27) 
and 2.42 for E and N (95% CI, 2.40–2.44).
Of the initial positive results, results from paired URT and LRT 
samples were used to evaluate positive result characteristics ac-
cording to the sample types. Results for 3,832 samples were 
Table 1. Number of SARS-CoV-2 rRT-PCR testing performed by clinical laboratories in Korea from February 7th to June 4th, 2020
Medical institutions, N (%) Independent clinical laboratories, N (%) Total, N (%)
Tests 533,615 (100) 1,356,704 (100) 1,890,319 (100)
Positive results 13,772 (2.6) 29,797 (2.2) 43,569 (2.3)
Negative results 518,023 (97.1) 1,319,162 (97.2) 1,837,185 (97.2)
Invalid/indeterminate results 1,820 (0.3) 7,745 (0.6) 9,565 (0.5)
Abbreviations: rRT-PCR, real-time reverse transcription PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Huh HJ, et al.
Surveillance of COVID-19 testing in Korea
https://doi.org/10.3343/alm.2021.41.2.225 www.annlabmed.org  227
obtained from 1,916 paired URT (nasopharyngeal swab [NPS] 
or nasopharyngeal/oropharyngeal swab [NPS/OPS]) and LRT 
(sputum) samples, including 909 sets of NPS and sputum 
samples and 1,007 sets of NPS/OPS and sputum samples. The 
distributions of E, RdRp, and N gene Ct values in the paired 
samples are presented in Table 2. No statistically significant dif-
ferences in gene Ct values were observed between the paired 
URT and LRT samples, except in the N gene for NPS and spu-
tum samples.
Surveillance for emerging pathogens is a common practice; 
however, daily surveillance is uncommon [10, 11]. The labora-
tory-based SARS-CoV-2 surveillance system in our study can 
provide daily laboratory data for monitoring SARS-CoV-2 rRT-
PCR testing results in Korea and is being used successfully in a 
timely fashion. Our study showed that clinical laboratories in Ko-
rea responded quickly to the COVID-19 outbreak, with SARS-
CoV-2 rRT-PCR testing beginning 16 days after the first con-
firmed case in the country, and that the testing capacity in-






NPS vs. sputum (N=909) NPS/OPS vs. sputum (N=1,007)
Ct value, Median 
(IQR)
Ct difference, Median 
(IQR)
Ct value, Median 
(IQR)
Ct difference, Median 
(IQR)
NPS Sputum Sputum-NPS P* NPS/OPS Sputum Sputum-NPS P*
E 24.61 (19.20–29.51) 24.57 (19.57–29.06) 0.22 (–0.16–0.59) >0.05 24.69 (18.59–29.65) 24.82 (19.24–29.52) 0.19 (–0.14–0.51) >0.05
RdRp 25.65 (20.33–30.42) 25.82 (20.95–30.12) 0.28 (–0.07–0.64) >0.05 25.66 (19.97–30.86) 25.89 (20.49–30.72) 0.29 (–0.03–0.61) >0.05
N 26.97 (21.58–31.29) 27.12 (22.31–31.34) 0.49 (0.11–0.88) 0.034 26.89 (21.22–31.79) 27.18 (21.97–31.95) 0.43 (0.07–0.80) >0.05
*Bonferroni-corrected P.
Abbreviations: COVID-19, coronavirus disease 2019; Ct, threshold cycle; E, envelope; IQR, interquartile range; N, nucleocapsid; NPS, nasopharyngeal swab; 
OPS, oropharyngeal swab; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Fig. 1. Monitoring of SARS-CoV-2 rRT-PCR testing performed by clinical laboratories in Korea from February 7th to June 4th, 2020. Con-
firmed case numbers were derived from the KCDC data (http://ncov.mohw.go.kr/).
Abbreviations: COVID-19, coronavirus disease 2019; EUA, emergency use authorization; KCDC, Korean Centers for Disease Control and Prevention; MFDS, 
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creased rapidly thereafter. Of note, clinical laboratories consis-
tently conducted over 70,000 tests weekly during the study pe-
riod, although the number of confirmed patients sharply de-
creased since the peak in the first week of March 2020.
Recent studies have reported that SARS-CoV-2 detection sen-
sitivity is greater for LRT samples than for URT samples [12-15]. 
Using paired sample analysis, Lin, et al. [14] demonstrated that 
the detection rates of SARS-CoV-2 for sputum samples were sig-
nificantly higher than those for throat swabs. In our study, paired 
sample analysis, with positive results from both URT and LRT 
samples, showed that the Ct value differences between sample 
types were generally not significant. Although the N gene Ct 
value differences between NPS and sputum were significant, the 
median Ct difference (0.49) was low. As these results were de-
rived from initial positive results from newly diagnosed COVID-19 
patients, it is possible that several patients were paucisymptom-
atic or asymptomatic, without productive sputum.
This study has several limitations. We have reported not the 
number of COVID-19 patients but the number of SARS-CoV-2 
rRT-PCR testing. Additionally, we did not collect clinical informa-
tion, as the study was based on laboratory surveillance data re-
garding testing capacities and positive result details. In addition, 
detailed information, such as sample type, was not available for 
all negative results.
In summary, this laboratory surveillance report for SARS-
CoV-2 rRT-PCR testing provided a timely assessment of testing 
capacities of clinical laboratories and positive result characteris-
tics, according to sample type and assays, for the first few 
months of the COVID-19 outbreak in Korea. Clinical laboratories 
rapidly expanded their testing capacity in response to the CO-
VID-19 outbreak, with a peak daily testing capacity of 34,193 
tests. This rapid expansion in testing capacity is a critical com-
ponent of the national response to the ongoing pandemic.
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